Table 2 Exposure to treatment and compliance
Deferasirox FCT, N = 53 | |
|---|---|
Duration of exposure (days), mean (SD) | 571.5 (215.28) |
Duration of exposure categories (weeks), n (%) | |
< 24 | 6 (11.3) |
24 to < 52 | 4 (7.5) |
52 to < 72 | 8 (15.1) |
72 to < 100 | 11 (20.8) |
≥ 100 | 24 (45.3) |
Patient treatment years | 82.9 |
Average actual dose (mg/kg/day), mean (SD) | 21.3 (4.63) |
Average actual dose category (mg/kg/day), n (%) | |
< 10.5 | 1 (1.9) |
10.5 to < 17.5 | 10 (18.9) |
17.5 to < 24.5 | 27 (50.9) |
≥ 24.5 | 15 (28.3) |
Compliance | |
Relative consumed tablet count (%), mean (SD) | 90.2 (10.07) |
Persistence | |
Continuous use of deferasirox FCT with no interruption for ≥ 60 days, n (%) | |
Up to 3 months (n = 53) | 53 (100.0) |
Up to 6 months (n = 51) | 51 (100.0) |
Up to 9 months (n = 47) | 47 (100.0) |
Up to 12 months (n = 46) | 46 (100.0) |
Continuous use of deferasirox FCT with no interruption for ≥ 30 days, n (%) | |
Up to 3 months (n = 53) | 52 (98.1) |
Up to 6 months (n = 51) | 50 (98.0) |
Up to 9 months (n = 47) | 46 (97.9) |
Up to 12 months (n = 46) | 44 (95.7) |